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Question 1: “Will hot flushes go
away if I do not take HT?”
The menopausal transition stage, which
marks the beginning of the peri-
menopause, the phase in a female’s life
associated with clinical changes that
signal the end of reproductive
capabilities, is divided into early and
late phases.  Women in the early phase
often have shortened menstrual cycles,
typically defined as a variation of more
than 7 days in cycle length compared
with their regular pattern.  During the
late phase, skipping of periods occurs
and intervals of 60 days or more occur
between periods.  It is during the late
phase of the peri-menopause that the
hot flushes occur, although there are
studies that report up to 40% of women
beginning to have episodes of hot
flushing and night sweating at least 10
years prior to their menopause.  The
post-menopausal stage is also divided
into early and late phases.  The early
phase includes the first five years after
the last menstrual period.  The late phase
extends for the remainder of the woman’s
life.  Onset of peri-menopause occurs
between 45 and 47 years of age,
typically lasts 4 to 6 years, with the post-
menopause generally beginning at 51
years of age.  Some women may begin
their transition in their early 40’s, but the
decade between 45 and 55 years
typically encompasses the transition
from per i -menopause to post-
menopause.
As the hormonal levels shift, with
estrogens decreasing, FSH and LH
increasing, 85-90% of women begin to
experience vasomotor instability
described as hot flushes and night
sweats, attributable to the effect of
decreasing estrogen levels on brain
activity.  Although the exact mechanism
responsible for hot flushes remains
unclear, numerous neuroregulators are
involved: LH levels surge before the
flush, hypothalamic norepinephrine
activity increases, adrenocorticotrophin
hormone and growth hormone levels
rise after the flush, and beta endorphin
levels decrease at the onset of a flush
and rise significantly after it subsides.
It is during this time that susceptible
women begin to have problems related
to insomnia, irritability and mood
disturbances.  Vasomotor symptoms
tend to occur with the onset of rapid-
eye-movement sleep thus disrupting
normal sleep architecture.  The resulting
day time fatigue, poor concentration and
dysphasia may be difficult to differentiate
from the somatic symptoms associated
with depression.
Approximately 60% of patients will
experience profound physiological
changes with significant discomfort.
With the flushes there is a peripheral
skin temperature change of between 5
and 9°C, and there can be a change in
basal heart rate of up to 12-20 beats/min.
 Women can experience up to ten flushes
per day and chronic sleep disturbance
results if intense night sweats wake the
patient four to five times each night.  The
resultant sleep deprivation may be
associated with psychological changes,
namely difficulty in making decisions,
anxiety, irritability and loss of confidence.
 The psychological problems tend to be
self-limiting for most women, but 25%
of symptomatic women still experience
hot flushes and night sweats 5 years
after the menopause.  Generally, the
average duration of the vasomotor
symptoms is 12-24 months, even though
FSH and LH levels remain high until  65
years of age, after which they slowly
decrease.
Question 2: “Will low dose HT
relieve hot flushes?”
Currently, systemic estrogen or HT is the
only therapy that effectively treats
vasomotor and genito-urinary symptoms
while also preserving bone.  Concerns
initially raised by the WHI study about
the  long-term side effects of HT have
resulted in much confusion about how
to reduce r isks while rel ieving
menopausal symptoms and preserving
bone heal th.  The most recent
recommendations have been to
advocate the individualisation of
treatment plans, taking into account the
patient’s specific risk factors. This
includes using the lowest effective doses
and reviewing duration of therapy
according to treatment goals and patient
risk factors.  As with conventional doses
of HT, effective low-dose estrogen
regimens should decrease vasomotor
symptoms, relieve genito-urinary
symptoms, prevent osteoporosis and
protect the endometrium.  The HOPE
study, amongst others, which compares
0.625 mg, 0.45 mg and 0.3 mg
respectively of conjugated equine
estrogen, has clearly shown that all
estrogen and combination regimens
decrease hot flushes, with low-dose
estrogen plus progestogen providing
results similar to standard combination
therapy with 0.625 mg of estrogen.
Adding progestogens to low/lower doses
of estrogen enhances the beneficial
effects of estrogen in relieving frequent
and severe flushes in women with an
intact uterus.  Low dose estrogen
alone is as effective as standard dose
estrogens in suppressing hot flushes
and night sweats in women without a
uterus.  Similar control of vasomotor
symptoms has been reported with
transdermal estrogen i.e. doses as low
as 0.02 mg/d effectively controlling hot
flushes as early as 2 weeks after the
patch is applied.  Symptoms have shown
a reduction of 84% after 12 weeks of
therapy.
Question 3: “Are alternative
medicines safe and effective for
hot flushes?”
Many women use herbal medicines, soy
and phytoestrogens for treatment of
menopausal symptoms.  Interest in soy
and isoflavones derived from soy has
been stimulated by epidemiological data
from Asian countries.  Women in several
Asian countries have less frequent and
less severe menopausal symptoms and
a lower incidence of breast cancer,
compared with women in western
countries.  The diet in Asian countries
is rich in soy and other sources of
phytoestrogens.
The role of these alternative therapies
is confusing, controversial and unsub-
stantiated.  Each of these therapies has
a “placebo beneficial effective” of
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approximately 40% whilst patients
generally take multiple agents.  There is
currently no scientifically derived
database, with widespread promotion
of the products being misleading and
commonly not evaluated by the FDA.
The following is a very brief synopsis of
some products:
Wild yam: Despite promotional claims,
the content of the plant does not convert
to progesterone when ingested or
applied topically as a cream.  Even
though diosgenin is found in the plant,
it needs to be extracted in the laboratory,
and will not be absorbed otherwise.
Significant symptomatic improvement of
hot flushes has not been shown to occur.
Phytoestrogens: These are plant-
derived compounds that have estrogenic
activity found in legumes, soy beans,
vegetables and cereals.  The most
abundant soy isoflavones, genistein and
daidzein, have received the most
attention as alternative treatments for
hot flushes.  Initial studies of the effect
of soy or isoflavone supplementation on
hot flushes produced conflicting results.
 Most studies have been of short duration
(<12 weeks) and comparisons are
difficult because of variations in product
dosage and scoring systems for
symptoms of hot flushes.  Some studies
reported a slight benefit (10-15%)
compared to placebo, whereas others
showed no significant benefit over
placebo.  The reduction in hot flushes
reported in the positive studies was
modest (40-54%) in comparison with the
80-90% reduction achieved with
hormone therapy, and not much more
than placebo effects in many trials.
Black cohosh:  This is not a
phytoestrogen, nor does it contain
phytoestrogens.  Its use has been
approved by the German Commission
E for the treatment of hot flushes for up
to 6 months.  Whereas early studies did
suggest that it had estrogenic activity,
more recent studies have shown that it
has no effect on serum levels of LH,
FSH, prolactin, SHBG or estradiol.  A 6
month study of the agent accompanied
by an extensive literature search shows
the plant to have a good safety profile.
Different extraction processes are used
in its production, with the result that there
are wide variations in the product
ingredients and it is often packaged in
combination with other plant products.
 Most studies of its efficacy are of limited
methodological quality and there is little
solid evidence from high-quality trials
that it works.
Red clover: It contains phytoestrogens
i.e. isoflavoid and coumestan, and has
estrogen-like activity in animal models.
 The limited available data on its effect
on hot flushes is not impressive.
Dong quai: It has no significant effect
on menopausal symptoms, endometrial
thickness or vaginal maturation.  Seldom
given on its own, it is generally
prescribed as part of a combination
specifically tailored to the individual
patient i.e. with wild yam, chaste tree,
black cohosh, milk thistle, cobelia etc.
Ginseng: Although considered to have
“tonic” effects, it also has the reputation
of being one of the most adulterated
products on the world market.  Its use
has been shown to improve fatigue,
insomnia, mood and depression.  No
significant improvement of menopausal
symptoms has been described.  Its use
is contraindicated in the presence of
breast cancer.
St John’s wort: It is widely used in
Germany and often combined with black
cohosh to treat menopausal hot flushes,
irritability, minor depression and
insomnia.  There are, to date, no clinical
trials evaluating its activity in menopause.
Kava: It has been shown to improve
irritability and insomnia but has been
banned in Germany, Switzerland, the
United Kingdom, Ireland, Australia and
Canada because of purpor ted
hepatotoxici ty.  I t  is  unwise to
recommend it as part of a treatment
regimen.
Chastetree: Frequently used for early
menopausal menstrual irregularity and
commonly a component of combination
formulations.  It is approved in Germany
for treating premenstrual syndrome,
mastalgia and irregularities of the
menstrual cycle.  There are currently no
studies to assess its effect on
menopause.  Safety data derived from
studies are reassuring.
Question 4: “I get blood clots.
which other products can I take
to relieve hot flushes?”
All patients presenting with a history of
thrombotic episodes and associated
menopausal systems for which
treatment is requested should be
invest igated.  The aim of  the
investigation is to exclude underlying
thrombophilia.  Investigations include
activated protein C, protein S, Leiden
Factor  V (act ivated prote in C
resistance), anti-thrombin 3, homo-
cysteine levels, prothrombin gene
220101 and exclusion of the anti-
phospholipid syndrome.  The issue of
hormonal supplementation and the risk
of thromboembolic disease should be
discussed if there is no evidence to
support an underlying thrombophilia,
and particularly if the thrombotic
episode was associated with a
predisposing event such as surgery, a
period of immobilisation, or air travel.
The patient should be given aspirin and
low dose HT, primarily as transdermal
administration.  If there is evidence of
thrombophilia, the current recommen-
dation would be to consider venlafaxine,
life-style modifications or clonidine.  If
all fails, and the meno-pausal symptoms
are particularly debilitating, full oral
anticoagulation and conventional HT
admin is te red  v ia  t ransder ma l
application could be considered.
Patients should be carefully selected
for the latter option and it would be
prudent to consult with the hema-
tologist.
Question 5: “How long should I
take HT to relieve my hot
flushes?”
It takes approximately one week for a
woman to detect some difference, and
3 weeks to 3 months to have a
significantly noticeable difference.
Patients should be seen 6 months after
commencing HT and then annually.
Serological estradiol levels need not
be monitored routinely and the
patient’s response to the HT treatment
is probably the best guide to its
efficacy.  However, in the case of
subcutaneous estradiol implants, further
administration of implants should be
considered once the serological level
of the estradiol is <400pg/h. These
patients require assessment of
serological estradiol  levels whenever
they become “symptomatic” and
request further implants.  A serological
level of >400pg/l excludes further
implants and the patient’s symptoms
are likely to be due to other conditions
i.e. hypothyroidism or depression. In
the latter group of patients the author
has used SSRIs as additional treatment
with significant improvements of
symptoms. Only once the estradiol
levels are <400pg/l should the implants
be re-inserted.
Therapy may be continued for at
least 5 years before re-assessing
whether continuance is necessary.  The
author does not recommend stopping
HT intermittently for “a rest” or during
winter “to see whether further HT is still
necessary”.
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